A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-Cytomegalovirus Activity of Maribavir [Camvia] in Recipients of Allogeneic Stem Cell Transplants.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-Cytomegalovirus Activity of Maribavir [Camvia] in Recipients of Allogeneic Stem Cell Transplants.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Maribavir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors ViroPharma
  • Most Recent Events

    • 02 Jun 2008 Results published in Blood, 1 June 2008, previously presented at ASH 2006, Orlando, Florida, USA, 2006.
    • 31 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top